研究等業績 - その他 - 成田 伸太郎
-
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Takamitsu Inoue, Takashi Obara, Mitsuru Saito, Teruaki Kumazawa, Shintaro Narita, Yohei Horikawa, Takeshi Yuasa, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi
Hinyokika kiyo. Acta urologica Japonica 54 ( 9 ) 581 - 5 2008年09月
From 2001 to 2006, 11 patients with MVAC-treated metastatic urothelial carcinoma received as a second-line therapy GDC therapy consisting of gemcitabine (1,000 mg/m2) on day land 8, docetaxel (80 mg/m2) on day 1 and carboplatin (AUC 5) on day 1 in each 21-day cycle. The 11 patients received a total of 42 cycles. The median progression-free survival and the median overall survival were 3 months (range 0-51) and 10 months (range 2-51), respectively. The median overall survival from diagnosis of the metastasis was 13.0 months (range 7-55). Complete response and partial response rates were 1/11 (9%) and 5/11 (45%), respectively. One- and two-year survival rates were 36 and 9%, respectively. Grade 3 or 4 hematologic toxicity included neutropenia (69.0%), thrombocytopenia (47.6%) and anemia (45.2%). Non-hematologic toxicity of grade 3 or 4 consisted mainly of diarrhea (23.8%) and anorexia (21.4%). GDC regimen as a second-line chemotherapy was effective in 54% of patients with MVAC-treated metastatic urothelial carcinoma, although the high incidence of hematologic toxicities and short period of progression-free survival remain to be major problems.
-
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Shintaro Narita, Alan So, Susan Ettinger, Norihiro Hayashi, Mototsugu Muramaki, Ladan Fazli, Youngsoo Kim, Martin E Gleave
Clinical cancer research : an official journal of the American Association for Cancer Research 14 ( 18 ) 5769 - 77 2008年09月
PURPOSE: GLI transcription factors mediate hedgehog signaling and have been implicated in several human malignancies, including prostate cancer. The objectives of this study were to characterize GLI2 expression levels in human prostate cancer cell lines and tissues to test the effect of antisense oligonucleotide (ASO) targeting GLI2 on androgen-independent (AI) prostate cancer cell lines. EXPERIMENTAL DESIGN: A tissue microarray was used to characterize differences in GLI2 expression in benign prostate hyperplasia, prostate cancer treated by neoadjuvant hormonal therapy and AI prostate cancer. The effects of GLI2 ASO on PC-3 cell growth and paclitaxel chemosensitivity were assessed in vitro and in vivo. Oligonucleotide spotted microarray analysis was used to determine alteration in GLI2 coregulated genes after ASO treatment. RESULTS: The expression of GLI2 was significantly higher in prostate cancer than in benign prostate hyperplasia, decreased after androgen ablation in a time-dependent fashion, but became highly expressed again in AI prostate cancer. GLI2 ASO treatment of PC-3 cells reduced GLI2 mRNA and protein levels in a dose-dependent manner. GLI2 knockdown increased PC-3 cell apoptotic rates and significantly decreased cell growth and modulated levels of apoptosis-related genes, such as Bcl2, Bcl-xL, and clusterin. GLI2 knockdown also changed levels of several cell cycle regulators, such as cyclin D1, p27, and PKC-eta. Systematic administration of GLI2 ASO in athymic mice significantly delayed PC-3 tumor progression and enhanced paclitaxel chemosensitivity. CONCLUSIONS: These findings suggest that increased levels of GLI2 correlates with AI progression and that GLI2 may be a therapeutic target in castrate-resistant prostate cancer.
-
A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer.
Naofumi Narita, Takeshi Yuasa, Norihiko Tsuchiya, Teruaki Kumazawa, Shintaro Narita, Takamitsu Inoue, Zhiyong Ma, Mitsuru Saito, Yohei Horikawa, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
BMC cancer 8 224 - 224 2008年08月
BACKGROUND: The purpose of this study was to evaluate the role of osteoprotegerin gene (OPG) polymorphisms as genetic modifiers in the etiology of prostate cancer (PCa) and disease progression. METHODS: Three hundred and sixty one patients with PCa and 195 normal controls were enrolled in the study, and two genetic polymorphisms, 149 T/C and 950 T/C in the putative promoter region of OPG, were genotyped. RESULTS: There was no significant difference in the genotype frequencies between PCa patients and controls (P = 0.939 and 0.294 for 149 T/C and 950 T/C polymorphisms, respectively). However, those patients with TC and TT genotypes in the 950 T/C polymorphism had a significantly increased risk of extraprostatic (age-adjusted odds ratio; aOR = 1.74 and 2.03 for TC and TT genotypes compared with the CC genotype, P = 0.028) and metastatic disease (aOR = 1.72 and 2.76 for TC and TT genotypes compared with the CC genotype, P = 0.009) compared with those with the CC genotype. In addition, analysis of the metastatic PCa patients (Stage D) showed that the presence of the T allele of the OPG 950 T/C polymorphism was an independent risk factor predicting survival by Cox proportional hazard regression analyses (P = 0.031). CONCLUSION: Progression of PCa may be influenced by an intrinsic genetic factor of the host's bone metabolism. The variant C allele of 950 T/C in the OPG promoter may play a major role as a genetic safe guard against progression in patients with PCa.
-
Prognostic significance of HIF-1alpha polymorphisms in transitional cell carcinoma of the bladder
Junichi Nadaoka, Yohei Horikawa, Mitsuru Saito, Teruaki Kumazawa, Takamitsu Inoue, Shintaro Narita, Takeshi Yuasa, Shigeru Satoh, Hiroyuki Nishiyama, Osamu Ogawa, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 179 ( 4 ) 320 - 320 2008年04月
研究発表要旨（国際会議）
-
Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder.
Junichi Nadaoka, Yohei Horikawa, Mitsuru Saito, Teruaki Kumazawa, Takamitsu Inoue, Shintaro Narita, Takeshi Yuasa, Shigeru Satoh, Hiroyuki Nishiyama, Osamu Ogawa, Norihiko Tsuchiya, Tomonori Habuchi
International journal of cancer 122 ( 6 ) 1297 - 302 2008年03月
Recently, two single nucleotide polymorphisms in the hypoxia-inducible factor-1 alpha (HIF-1 alpha) gene, P582S and A588T, were shown to cause significantly higher transcriptional activity than the wild type. We investigated the association between the HIF-1 alpha polymorphisms and the incidence and progression of transitional cell carcinoma of the bladder, and the relationship between the polymorphisms and the tissue vascular endothelial growth factor (VEGF) level or microvessel density (MVD). A total of 219 patients with bladder cancer and 464 healthy native Japanese control subjects were enrolled. Tissue VEGF and HIF-1 alpha expression levels and the mean MVD were evaluated in 73 radical cystectomy specimens by immunohistochemistry. The HIF-1 alpha genotype did not significantly influence the incidence or disease status of bladder cancer. Among patients who underwent radical cystectomy, those with a variant allele had significantly worse disease-free survival (p = 0.001) and disease-specific survival (p = 0.006) than those without a variant allele. Multivariate analysis using a Cox proportional hazard model revealed that the presence of a variant allele was an independent predictor of disease-free survival (HR = 3.10, 95%CI = 1.38-6.99, p = 0.006). Although not statistically significant, the moderate/high expression levels of VEGF in tumor tissues were more frequently observed in patients with a HIF-1 alpha variant allele (11/13, 84.6%) than in those without (33/60, 55%, p = 0.063). The HIF-1 alpha polymorphisms may have a significant influence on the poor prognosis of the patients undergoing radical cystectomy for bladder cancer, while they seem to have no relation to the bladder cancer occurrence.
-
Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis.
Shintaro Narita, Norihiko Tsuchiya, Mitsuru Saito, Takamitsu Inoue, Teruaki Kumazawa, Takeshi Yuasa, Akira Nakamura, Tomonori Habuchi
The Prostate 68 ( 3 ) 321 - 35 2008年02月
BACKGROUND: Several studies have suggested that a high fat diet (HFD) may be a risk factor of prostate cancer (PCa). As a first step to delineate the molecular mechanisms underlying the enhanced progression of PCa under HFD, we investigated the differential gene expressions of a human PCa xenograft under HFD and a low fat diet (LFD). METHODS: LNCaP cells were subcutaneously injected in 20 nude mice, which were equally divided into two groups, the HFD group and LFD group. Oligonucleotide microarray analyses were performed using mice xenografts from HFD and LFD, and the results of candidate genes with a significant differential expression were validated by quantitative RT-PCR experiments. As for insulin-like growth factor I receptor (IGF-IR), protein expression levels were further examined by immunohistochemistry in xenograft tissues and in 78 radical prostatectomy specimens. RESULTS: Tumor volume and serum PSA levels were significantly higher in the HFD group than in the LFD group (P<0.001 and P=0.006, respectively). We found 64 up-regulated genes (0.19%) and 14 down-regulated genes (0.04%) with more than twofold differences in the HFD xenograft. IGF-IR, TNFRSF, and LPL showed striking differences in the quantitative RT-PCR experiment. Immunostaining further revealed marked enhanced IGF-IR expression in the HFD xenograft. In human PCa, the lowest IGF-IR immunoreactivity group tended to have the lowest body mass index in both normal and PCa epithelium. CONCLUSION: HFD induced remarkable up- and down-regulation of mRNA of a substantial number of genes. Furthermore, the IGF-I system may be involved in the HFD-associated enhanced progression of PCa.
-
APP-085 腎細胞癌患者におけるDNAの完全性(副腎腫瘍・腎腫瘍/マーカー・臨床,総会賞応募ポスター,第96回日本泌尿器科学会総会)
土谷 順彦, 熊澤 光明, 井上 高光, 成田 伸太郎, 齋藤 満, 堀川 洋平, 小原 崇, 湯浅 健, 佐藤 滋, 羽渕 友則
日本泌尿器科学会雑誌 ( 一般社団法人 日本泌尿器科学会 ) 99 ( 2 ) 252 - 252 2008年
-
Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
Hisami Fukuda, Norihiko Tsuchiya, Shintaro Narita, Teruaki Kumazawa, Yohei Horikawa, Takamitsu Inoue, Mitsuru Saito, Takeshi Yuasa, Shinobu Matsuura, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
Oncology reports 18 ( 5 ) 1155 - 63 2007年11月
Vascular endothelial growth factor (VEGF), one of the most potent angiogenic factors, is suggested to play a crucial role in tumor neovascularization and is associated with tumor progression and metastasis in prostate cancer. This study evaluated the significance of the VEGF T-460C polymorphism in the risk and the progression of prostate cancer. In a case-control experiment, 270 patients with prostate cancer and 252 male controls were investigated to assess the association of the VEGF T-460C polymorphism with the risk of prostate cancer. Prostate-specific antigen (PSA) recurrence in 95 patients who underwent radical prostatectomy and survival in 99 patients with metastases at diagnosis were analyzed to evaluate the influence of the polymorphism in cancer progression. The CC and TC genotypes of the polymorphism were associated with significantly higher rates of PSA recurrence after radical prostatectomy than the TT genotype and were independent predictors of PSA recurrence (P=0.011) in a multivariate analysis. In contrast, metastatic prostate cancer patients with the TT genotype showed significantly worse survival as compared to the CC and TC genotypes. In a multivariate analysis, the TT genotype was an independent predictor of cancer-specific survival (P=0.006). The VEGF T-460C polymorphism may have a substantial impact on both PSA recurrence after radical prostatectomy and survival in advanced prostate cancer. The molecular mechanisms of the polymorphism on the differing status in prostate cancer should be elucidated in further studies.
-
Lymphatic invasion is a prognostic factor for bladder cancer treated with radical cystectomy.
Yohei Horikawa, Teruaki Kumazawa, Shintaro Narita, Takamitsu Inoue, Takeshi Yuasa, Shinobu Matsuura, Hiroshi Nanjo, Shigeru Satoh, Norihiko Tsuchiya, Tomonori Habuchi
International journal of clinical oncology 12 ( 2 ) 131 - 6 2007年04月
BACKGROUND: We aimed to elucidate the significance of pathological prognostic factors in patients with bladder cancer treated with radical cystectomy and pelvic lymphadenectomy focusing on the association between lymphatic invasion and disease recurrence. METHODS: Ninety-one patients with ladder cancer who had undergone radical cystectomy were examined retrospectively. Clinicopathological findings and clinical outcomes were analyzed. Patients who received palliative cystectomy or neoadjuvant chemotherapy and patients who did not receive lymphadenectomy owing to a poor general condition or far advanced local disease status were excluded. RESULTS: Lymphatic invasion and lymph node involvement were present in 45.1% and 23.1% of patients, respectively. Multivariate analyses, using the Cox proportional hazards model, indicated that lymphatic invasion (hazard ratio [HR], 5.30; P = 0.007) and lymph node involvement (HR = 3.05; P = 0.016) were independent prognostic factors for disease-specific survival. Of the 91 patients, 29 (31.9%) had recurrent disease during the follow-up period. The rate of recurrence in patients with lymphatic invasion and without lymph node involvement was 50% (11/22), which was not significantly different from that in patients with both lymphatic invasion and lymph node involvement (73.7%; 14/19; P = 0.121), indicating a high risk of disease recurrence in patients with bladder cancer with lymphatic invasion even in the absence of the lymph node involvement. CONCLUSION: In patients with bladder cancer treated with radical cystectomy, lymphatic invasion is an independent prognostic factor for disease-specific and disease-free survival. Patients with lymphatic invasion have a high risk of disease recurrence after radical cystectomy even in the absence of lymph node involvement.
-
Clinical implication of vascular endothelial growth factor (VEGF) T-460C polymorphism in the risk and progression of prostate cancer
Norihiko Tsuchiya, Hisami Fukuda, Shintaro Narita, Teruaki Kumazawa, Yohei Horikawa, Takamitsu Inoue, Mitsuru Saito, Takeshi Yuasa, Shinobu Matsuura, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 177 ( 4 ) 53 - 53 2007年04月
研究発表要旨（国際会議）
-
Gene expression in response to high-fat feeding in human prostate cancer xenograft model
Shintaro Narita, Norihiko Tsuchiya, Mitsuru Saito, Takamitsu Inoue, Teruaki Kumazawa, Yohei Horikawa, Takeshi Yuasa, Shinobu Matsuura, Shigeru Satoh, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 177 ( 4 ) 48 - 48 2007年04月
研究発表要旨（国際会議）
-
Identifying genetic polymorphisms which predict adverse effects of MVAC in patients with urothelial cancers
Norihiko Tsuchiya, Takamitsu Inoue, Shintaro Narita, Teruaki Kumazawa, Mitsuru Saito, Yohei Horikawa, Takeshi Yuasa, Shinobu Matsuura, Shigeru Satoh
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 177 ( 4 ) 81 - 81 2007年04月
研究発表要旨（国際会議）
-
APP-024 前立腺癌の進展における Osteoprotegerin の役割(第95回日本泌尿器科学会総会)
成田 直史, 湯浅 健, 土谷 順彦, 熊澤 光明, 堀川 洋平, 成田 伸太郎, 齋藤 満, 井上 高光, 松浦 忍, 佐藤 滋, 羽渕 友則
日本泌尿器科学会雑誌 ( 一般社団法人 日本泌尿器科学会 ) 98 ( 2 ) 252 - 252 2007年
-
PP-618 進行性前立腺癌の予後におけるhGH, IGF-IならびにIL-6遺伝子多型の関与(第95回日本泌尿器科学会総会)
土谷 順彦, 成田 伸太郎, 熊澤 光明, 井上 高光, 馬 智勇, 齋藤 満, 堀川 洋平, 湯浅 健, 松浦 忍, 佐藤 滋, 小川 修, 羽渕 友則
日本泌尿器科学会雑誌 ( 一般社団法人 日本泌尿器科学会 ) 98 ( 2 ) 551 - 551 2007年
-
Radical nephroureterectomy as initial treatment for carcinoma in situ of upper urinary tract.
Takeshi Yuasa, Norihiko Tsuchiya, Shintaro Narita, Takamitsu Inoue, Mitsuru Saito, Teruaki Kumazawa, Yohei Horikawa, Shinobu Matsuura, Shigeru Satoh, Hiroshi Nanjo, Tomonori Habuchi
Urology 68 ( 5 ) 972 - 5 2006年11月
OBJECTIVES: Transitional cell carcinoma in situ (CIS) of the upper urinary tract is a relatively rare disease, and treatment guidelines remain to be defined. In this study, we evaluated the outcomes after radical nephroureterectomy as the initial therapy for upper urinary tract CIS. METHODS: Eight patients treated with radical nephroureterectomy after the diagnosis of upper urinary tract CIS from December 1999 to May 2004 were entered in this study. The diagnosis criteria included positive voided urinary cytology; negative multiple random biopsies of the bladder; negative radiographic studies, including retrograde pyelography and computed tomography; and serial positive cytology results in selective ipsilateral urine samples. RESULTS: The median follow-up period was 56 months. The presence of CIS was confirmed pathologically in all patients. Two patients had more invasive lesions (pT1 and pT2), although retrospective evaluation revealed no infiltrative lesions. Intravesical recurrence was found in 5 patients, whose median recurrence-free period was 16 months. These heterotopic urothelial recurrences did not affect patient survival, and all 8 patients were alive without disease at last follow-up. CONCLUSIONS: Although radical nephroureterectomy may be overtreatment for some patients with upper urinary tract CIS, excellent survival outcomes can be accomplished. In addition, the presence of concomitant invasive lesions, which cannot be identified on pretreatment examination in a substantial subset of patients with CIS, should be taken into account. Although the number of patients in this study was small, the results support the view that nephroureterectomy should remain a standard option for the initial treatment of this disease.
-
Bladder acellular matrix grafting regenerates urinary bladder in the spinal cord injury rat.
Takashi Obara, Shinobu Matsuura, Shintaro Narita, Shigeru Satoh, Norihiko Tsuchiya, Tomonori Habuchi
Urology 68 ( 4 ) 892 - 7 2006年10月
OBJECTIVES: To assess the feasibility of bladder acellular matrix (BAM) grafting onto the bladder of rats with spinal cord injury (SCI). METHODS: Female Wistar rats, weighing 100 to 150 g, were divided into four groups: neurologically intact groups with sham operation or BAM grafting and SCI rats with or without BAM grafting (grafted groups, n = 15 each; nongrafted groups, n = 5 each). The BAM was prepared from other normal rat bladder tissue. During BAM surgery, the rats underwent partial cystectomy, followed by BAM grafting as a bladder augmentation. The SCI was created by compressing the spinal cord at the 10th thoracic level. BAM grafting in SCI rats was performed 2 to 3 weeks after SCI. At 2, 4, and 12 weeks after grafting, cystometry was performed with the rats under pentobarbital anesthesia, and the bladders were subsequently harvested and immunostained with anti-PGP9.5, uroplakin III, and alpha-smooth muscle actin antibodies (n = 5 each time). For comparison, similar examinations were performed in the nongrafted groups (n = 5 each). RESULTS: Regenerated urothelium, smooth muscles, and nerve fibers in the grafted BAM appeared at 2, 4, and 12 weeks, respectively, in both intact and SCI rats. Immunohistologic examination showed that these regenerated tissues inherited each characteristic of the host bladder tissue. The grafted BAM itself also showed the proper storage function of distensibility in the intact and SCI groups receiving BAM. CONCLUSIONS: Our data have indicated that BAM grafting is feasible, even in animals with spinal injury, suggesting that BAM may be one of the alternatives for patients with a neurogenic bladder who require augmentation enterocystoplasty in clinical situations.
-
Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients.
Takamitsu Inoue, Takuo Ito, Shintaro Narita, Yohei Horikawa, Norihiko Tsuchiya, Hideaki Kakinuma, Mutsuki Mishina, Eijiro Nakamura, Tetsuro Kato, Osamu Ogawa, Tomonori Habuchi
Cancer letters 240 ( 1 ) 41 - 7 2006年08月
The association between four BCL10 single nucleotide polymorphisms at codons 5, 8, 162, and intron 1 and the susceptibility or progression for germ cell tumors (GCTs) was investigated in 73 testicular GCT patients and 72 controls. GCT patients with metastatic disease were more likely to have a variant type allele of the polymorphisms at codon 5 (age-adjusted odds ratio (aOR)=6.25; 95% CI=1.09-35.83; P=0.040) and codon 8 (aOR=4.63; 95% CI=1.35-15.93; P=0.015) than those with the localized disease. Therefore, BCL10 polymorphisms at codons 5 and 8 may play a role in the progression to advanced stage GCTs.
-
Association of XRCC1 gene polymorphisms with the susceptibility and chromosomal aberration of testicular germ cell tumors.
Norihiko Tsuchiya, Mutsuki Mishina, Shintaro Narita, Teruaki Kumazawa, Takamitsu Inoue, Yohei Horikawa, Hideaki Kakinuma, Takeshi Yuasa, Shinobu Matsuura, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
International journal of oncology 28 ( 5 ) 1217 - 23 2006年05月
It is known that many genomic and genetic alterations caused by aging or environmental factors are responsible for cancer development and progression. XRCC1 is involved in the repair of DNA single-strand breaks formed by exposure to ionizing radiation and alkylating agents. The objective of this study was to investigate the association of genomic alterations and the susceptibility of testicular germ cell tumors with XRCC1 polymorphisms. Two polymorphisms of XRCC1, Arg194Trp and Arg399Gln, were genotyped in 83 patients with testicular germ cell tumors (TGCT) and 87 male controls. Allelic imbalances (AI) were evaluated using 4 microsatellite markers in a subgroup of 50 patients. Patients with at least one Gln allele of the Arg399Gln polymorphism had an increased risk of TGCT than those with the Arg/Arg genotype (aOR=1.775, 95% CI=1.045-3.016, P=0.034). Furthermore, the increased risk associated with the Gln allele against the Arg homozygote was more strongly observed in patients with pure seminoma (aOR=2.242, 95% CI=1.149-4.374, P=0.018) or with metastasis (aOR=2.481, 95% CI=1.267-4.862, P=0.008). In the Arg194Trp polymorphism, there was no significant difference in the genotype distribution between TGCT patients and the controls. In AI analysis, the frequency of AI was significantly higher in tumors with at least one Gln allele than those with the Arg/Arg genotype in D13S317 (P=0.010) and in a combination of 4 markers (0.51+/-0.32 vs 0.32+/-28, P=0.028). Our results suggest that the Gln allele of the XRCC1 Arg399Gln polymorphism may genetically modify the development and progression of TGCT through genomic instability.
-
Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.
Norihiko Tsuchiya, Lizhong Wang, Hiroyoshi Suzuki, Takehiko Segawa, Hisami Fukuda, Shintaro Narita, Masaki Shimbo, Toshiyuki Kamoto, Kenji Mitsumori, Tomohiko Ichikawa, Osamu Ogawa, Akira Nakamura, Tomonori Habuchi
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24 ( 13 ) 1982 - 9 2006年05月
PURPOSE: The prognosis of metastatic prostate cancer significantly differs among individuals. While various clinical and biochemical prognostic factors for survival have been suggested, the progression and response to treatment of those patients may also be defined by host genetic factors. In this study, we evaluated genetic polymorphisms as prognostic predictors of metastatic prostate cancer. PATIENTS AND METHODS: One hundred eleven prostate cancer patients with bone metastasis at the diagnosis were enrolled in this study. Thirteen genetic polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism or an automated sequencer with a genotyping software. RESULTS: Among the polymorphisms, the long allele (over 18 [CA] repeats) of insulin-like growth factor-I (IGF-I) and the long allele (over seven [TTTA] repeats) of cytochrome P450 (CYP) 19 were significantly associated with a worse cancer-specific survival (P = .016 and .025 by logrank test, respectively). The presence of the long allele of either the IGF-I or CYP19 polymorphisms was an independent risk factor for death (P = .019 or .026, respectively). Furthermore, the presence of the long allele of both the IGF-I and CYP19 polymorphisms was a stronger predictor for survival (P = .001). CONCLUSION: The prognosis of metastatic prostate cancer patients is suggested to be influenced by intrinsic genetic factors. The IGF-I (CA) repeat and CYP19 (TTTA) repeat polymorphisms may be novel predictors in prostate cancer patients with bone metastasis at the diagnosis.
-
Outcome of right hand-assisted retroperitoneoscopic living donor nephrectomy.
Shintaro Narita, Takamitsu Inoue, Shinobu Matsuura, Yohei Horikawa, Hideaki Kakinuma, Mitsuru Saito, Teruaki Kumazawa, Norihiko Tsuchiya, Shigeru Satoh, Tomonori Habuchi
Urology 67 ( 3 ) 496 - 500 2006年03月
OBJECTIVES: To compare the results of right and left hand-assisted retroperitoneoscopic living donor nephrectomy (HARDN) and assess the usefulness and feasibility of right HARDN. METHODS: A total of 68 HARDNs performed from July 2001 to February 2005 in Akita University Medical Center were entered into this study. Of these, 12 cases were right-sided HARDN. The reasons for selecting right HARDN were wandering right kidney in 4, multiple left renal arteries in 3, lower glomerular function presenting in the right kidney in 2 patients, and left renal stone, right renal cyst, and right renal aneurysm in 1 patient each. We compared the perioperative and postoperative results of the 12 right-sided HARDNs with those of the 56 left HARDNs. RESULTS: No significant differences were found between the two groups in the demographic data (ie, age, sex, number of renal arteries), except for the body mass index. None of the right HARDNs resulted in major complications or open conversion, but two left HARDNs required conversion to open surgery. No difference was found between the two groups regarding estimated blood loss, warm ischemia time, or time to oral intake, although the right HARDN group had a longer mean operative time. No significant differences were found in the recipient's postoperative graft function or in the frequency of delayed graft function. CONCLUSIONS: Right HARDN provided almost similar perioperative and postoperative outcomes compared with those of left HARDN. Our results indicate that right HARDN is a choice for living donor nephrectomy because of its technical feasibility, safety, and minimal invasiveness, which are comparable to those of left HARDN.